Johnson & Johnson $JNJ Position Raised by Atria Investments Inc

Atria Investments Inc lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 242,053 shares of the company’s stock after acquiring an additional 3,471 shares during the period. Atria Investments Inc’s holdings in Johnson & Johnson were worth $44,881,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $28,000. Evolution Wealth Management Inc. acquired a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $27,000. Semmax Financial Advisors Inc. raised its stake in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares in the last quarter. Compass Financial Services Inc boosted its position in Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after acquiring an additional 198 shares during the period. Finally, Signature Resources Capital Management LLC grew its stake in shares of Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after purchasing an additional 184 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $240.97 on Thursday. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $241.26. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $580.56 billion, a P/E ratio of 21.81, a PEG ratio of 2.31 and a beta of 0.35. The company’s 50-day simple moving average is $215.57 and its 200 day simple moving average is $195.51.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company had revenue of $24.28 billion for the quarter. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Raymond James Financial increased their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Guggenheim upped their price objective on shares of Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Wells Fargo & Company raised their target price on Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research report on Thursday, January 22nd. Freedom Capital downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. Finally, Royal Bank Of Canada lifted their price target on Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $233.73.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.